Stocks Comparison
Johnson & Johnson vs Pfizer: revenue, profit, margins and growth compared
Johnson & Johnson brought in $94.2B of revenue in fiscal 2025, Pfizer $62.6B in fiscal 2025. Revenue changed by +6.0% at Johnson & Johnson and -1.6% at Pfizer on the year before, so Johnson & Johnson grew faster. Johnson & Johnson kept 28.5% of its revenue as net profit, Pfizer 12.4%. Free cash flow was $19.7B at Johnson & Johnson and $9.1B at Pfizer.
Side by side, latest fiscal year
| JNJ | PFE | |
|---|---|---|
| Fiscal year ended | FY2025 (December 28, 2025) | FY2025 (December 31, 2025) |
| Revenue | $94.2B | $62.6B |
| Revenue growth | +6.0% | -1.6% |
| Net income | $26.8B | $7.8B |
| Net margin | 28.5% | 12.4% |
| Free cash flow | $19.7B | $9.1B |
| Free cash flow margin | 20.9% | 14.5% |
| Earnings per share (diluted) | $11.03 | $1.36 |
| Cash | $19.7B | $1.1B |
| Debt | $41.4B | $64.6B |
| Price to earnings | 24.6 | 21.1 |
| Market value | $653.6B | $163.4B |
| Dividend yield | 1.90% | 6.00% |
| Rank by revenue in sector | #9 of 523 · Health care | #13 of 523 · Health care |
Over the years
Questions about Johnson & Johnson and Pfizer
Which is bigger by revenue, Johnson & Johnson or Pfizer?
Johnson & Johnson is bigger by revenue: $94.2B in fiscal 2025, against $62.6B for Pfizer in fiscal 2025.
Which keeps more of its revenue as profit, Johnson & Johnson or Pfizer?
Johnson & Johnson had a net margin of 28.5% in fiscal 2025; Pfizer had 12.4% in fiscal 2025.
Which grew revenue faster, Johnson & Johnson or Pfizer?
In their latest fiscal years revenue changed by +6.0% at Johnson & Johnson and -1.6% at Pfizer.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.